Clinical trial NCT03437200: Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer
Official title: Phase II Trial in Inoperable œsophageal Cancer Evaluating the Feasibility of the Combination of Definitive Chemoradiation With the Immune Checkpoint Blockers Nivolumab +/- Ipilimumab
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Inoperable œsophageal Cancer
Keywords: œsophageal cancer nivolumab ipilimumab
Lead sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Sponsor class: NETWORK
First posted: 2018-02-19
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main objective of the trial is to assess the feasibility and the safety of the addition of immunotherapy with PD-1 antibody nivolumab +/- CTLA-4 antibody ipilimumab to concomitant chemoradiation therapy (CRT) in inoperable patients with early or locally advanced oesophageal cancer and to select the more promising experimental arm among the two possible combinations in terms of activity (based on progression free survival (PFS) at 12 months according to RECIST 1.1) for further evaluation in a phase III trial.

The secondary objectives will aim to evaluate progression-free survival, failure-free survival and overall survival and pattern of progression (including incidence of distance metastasis).


Eligibility criteria: Inclusion Criteria:

* Histologically proven oesophageal squamous cell carcinoma or adenocarcinoma
* Both early stage and locally advanced tumor patients (according to TNM staging version 8):
* T1, N1-3, M0 after complete work-up
* T2, N0-3, M0 after complete work-up
* T3, N0-3, M0
* Patient eligible for definitive chemoradiation and not considered for primary surgery after multidisciplinary meeting decision or patient refuses to undergo surgery
* Subject must be previously untreated with systemic treatment given as primary therapy for advanced or metastatic disease
* At least one measurable lesion by CT scan or MRI based on RECIST version 1.1 with radiographic tumor assessment performed within 28 days prior to randomization
* Availability of adequate tissue in terms of quality and quantity for immunohistochemical staining for PDL-1
* WHO performance status 0 or 1
* Adequate organ function within 14 days prior to randomization

Exclusion Criteria:

* Cancer of cervical oesophagus (15 to 19 cm from dental ridge)
* Known Her2 positive adenocarcinoma
* Weight loss \> 15 % over the last 3 months without improvement after nutritional support
* Patient with cardiac dysfunction e.g. symptomatic congestive heart failure, uncontrolled hypertension
* Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS), hepatitis B or hepatitis C.
* Any prior treatment for advanced disease including treatment with an anti-Programmed Death receptor-1 (PD-1), anti-Programmed Death-1 ligand-1 (PD-L1), anti-PD-L2, anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4) antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
* Live vaccines within 30 days prior to the first dose of study therapy. Examples of live vaccines include, but are not limited to the following: measles, mumps, rubella, chicken pox, yellow fever, H1N1 flu, rabies, BCG, and typhoid vaccine
* History of hypersensitivity to study drugs or any excipient (refer to SmPCs for ipilimumab, nivolumab, 5-FU and oxaliplatin)
* Current participation or treatment with an investigational agent or use of an investigational agent within 4 weeks of the first dose of study treatment
* Serious comorbidity or life expectancy less than one year
* Contraindication to chemoradiation therapy
* Treatment history of radiotherapy
* Child-Pugh B/C and patients with history of acute or chronic pancreatitis
* Patient with Type I diabetes mellitus, or skin disorders
* Known severe systemic autoimmune disease affecting the lungs or the bowel
* Known contraindication to CT scans with IV contrast
* Chronic use of immunosuppressive agents and/or systemic corticosteroids or any use in the last 15 days prior to enrollment
* Active autoimmune disease that has required systemic treatment in past 2 years
* Autoimmune paraneoplastic syndrome requiring immunosuppressive or dedicated treatment
* History of any other hematologic or primary solid tumor malignancy, unless in remission for at least 5 years.

Primary outcomes:
measure: 12-Month Progression-free survival using RECIST 1.1
timeFrame: 3.8 years from first patient in
Secondary outcomes:
measure: Best overall response according to RECIST 1.1
timeFrame: 3.8 years from first patient in
measure: Pattern of first cause of progression (either local relapse/progression,either regional relapse/progression, either distant metastasis)
timeFrame: 3.8 years from first patient in
measure: Progression-free survival using RECIST 1.1
timeFrame: 3.8 years from first patient in
measure: Failure-free survival
timeFrame: 3.8 years from first patient in
measure: Overall survival
timeFrame: 3.8 years from first patient in
measure: Percentage of patients receiving the planned chemoradiation
timeFrame: 3.8 years from first patient in
measure: Relative dose intensity of oxaliplatinum
timeFrame: 3.8 years from first patient in
measure: Relative dose intensity of 5FU
timeFrame: 3.8 years from first patient in
Other outcomes:
Locations:
city: Paris
country: France
facility: Assistance Publique - Hopitaux de Paris - La Pitie Salpetriere
city: Villejuif
country: France
facility: Institut Gustave Roussy
city: Barcelona
country: Spain
facility: Hospital Del Mar
city: Barcelona
country: Spain
facility: Institut Catala d'Oncologia - ICO Badalona - Hospital De Mataro
city: Barcelona
country: Spain
facility: Institut Catala d'Oncologia - ICO L'Hospitalet - Hospital Duran i Reynals (Institut Catala D'Oncologia)
city: Las Palmas De Gran Canaria
country: Spain
facility: Hospital Universitario de Gran Canaria Doctor Negrin
city: Madrid
country: Spain
facility: Hospital Universitario 12 De Octubre
Study officials:
affiliation: INSTITUT GUSTAVE ROUSSY, Paris, France
name: Eric Deutsch
role: PRINCIPAL_INVESTIGATOR
affiliation: UNIVERSITY MEDICAL CENTER MAINZ, Germany
name: Markus Moehler
role: PRINCIPAL_INVESTIGATOR
References: